Found: 26
Select item for more details and to access through your institution.
Letter: Histological changes among asymptomatic chronic HBV carriers with normal alanine aminotransferase levels—Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1254, doi. 10.1111/apt.17784
- By:
- Publication type:
- Article
Editorial: Liver hypercortisolism as a potential target for MASH treatment—Authors' reply.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Editorial: Unravelling the relationship between periodontal disease and inflammatory bowel disease.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Letter: Abdominal pain in patients with inflammatory bowel disease in remission ‐ A look beyond psychosocial factors. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1250, doi. 10.1111/apt.17775
- By:
- Publication type:
- Article
Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—the MAFLD fibrosis score. Authors' reply.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Development of a model to identify patients who do not need oesophageal biopsies when eosinophilic oesophagitis is suspected.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1143, doi. 10.1111/apt.17772
- By:
- Publication type:
- Article
Editorial: On‐demand vonoprazan for NERD – when should it be 'demanded'? Authors' reply.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Letter: Histological changes among asymptomatic chronic HBV carriers with normal alanine aminotransferase levels.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1252, doi. 10.1111/apt.17760
- By:
- Publication type:
- Article
Letter: The importance of histological assessment—a further stride in STRIDE. Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1246, doi. 10.1111/apt.17763
- By:
- Publication type:
- Article
Systematic review with meta‐analysis: Diagnostic performance of faecal calprotectin in distinguishing inflammatory bowel disease from irritable bowel syndrome in adults.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1120, doi. 10.1111/apt.17754
- By:
- Publication type:
- Article
Editorial: Liver hypercortisolism as a potential target for MASH treatment.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis—Authors' reply.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1243, doi. 10.1111/apt.17750
- By:
- Publication type:
- Article
Letter: Abdominal pain in inflammatory bowel disease patients in remission—A look beyond psychosocial factors.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1248, doi. 10.1111/apt.17745
- By:
- Publication type:
- Article
Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—The MAFLD fibrosis score.
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Editorial: On‐demand vonoprazan for NERD—when should it be 'demanded'?
- Published in:
- 2023
- By:
- Publication type:
- Editorial
Antibiotic use as a risk factor for irritable bowel syndrome: Results from a nationwide, case–control study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1175, doi. 10.1111/apt.17736
- By:
- Publication type:
- Article
In severe alcohol‐related hepatitis, acute kidney injury is prevalent, associated with mortality independent of liver disease severity, and can be predicted using IL‐8 and micro‐RNAs.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1217, doi. 10.1111/apt.17733
- By:
- Publication type:
- Article
Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: Prospective longitudinal follow‐up study.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1163, doi. 10.1111/apt.17735
- By:
- Publication type:
- Article
Association between gut‐derived endotoxins and porto‐sinusoidal vascular disorder with portal hypertension.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1205, doi. 10.1111/apt.17727
- By:
- Publication type:
- Article
First in human randomised trial of J2H‐1702: A novel 11β‐hydroxysteroid dehydrogenase type 1 inhibitor for non‐alcoholic steatohepatitis treatment.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1132, doi. 10.1111/apt.17726
- By:
- Publication type:
- Article
MAFLD fibrosis score: Using routine measures to identify advanced fibrosis in metabolic‐associated fatty liver disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1194, doi. 10.1111/apt.17722
- By:
- Publication type:
- Article
Therapeutic drug monitoring of methotrexate in patients with Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1151, doi. 10.1111/apt.17719
- By:
- Publication type:
- Article
Letter: The importance of histological assessment—a further stride in STRIDE.
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
Tenofovir disoproxil fumarate versus tenofovir alafenamide on risk of osteoporotic fracture in patients with chronic hepatitis B: A nationwide claims study in South Korea.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1185, doi. 10.1111/apt.17716
- By:
- Publication type:
- Article
Letter: Tofacitinib, vedolizumab and ustekinumab in patients with ulcerative colitis.
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
Issue Information.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2023, v. 58, n. 11/12, p. 1117, doi. 10.1111/apt.17097
- Publication type:
- Article